Disc Medicine (IRON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of three Class III nominees to the Board of Directors: Donald Nicholson, John Quisel, and William White, each recommended for election by the Board.
Advisory vote to approve compensation paid to named executive officers, with Board recommending approval.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended by the Board.
Board of directors and corporate governance
Board recommends the election of three Class III director nominees at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, with Board recommending approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Disc Medicine
- All proposals, including director elections and auditor ratification, were approved by stockholders.IRON
AGM 202618 Jun 2026 - Bitopertin and selcodebart show strong, durable efficacy, with pivotal data expected in Q4 2026.IRON
Study update15 Jun 2026 - Pivotal data and regulatory milestones for key anemia programs are expected by year-end.IRON
Jefferies Global Healthcare Conference 20263 Jun 2026 - Late-stage pipeline targets EPP, MF anemia, and PV with pivotal data expected by 2027.IRON
Corporate presentation3 Jun 2026 - APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies.IRON
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Net loss widened to $63.5M as bitopertin's FDA review was delayed; cash runway extends to 2029.IRON
Q1 20265 May 2026 - Proxy covers director elections, say-on-pay, auditor ratification, and performance-based compensation.IRON
Proxy filing29 Apr 2026 - Phase III data for bitopertin and key pipeline readouts are expected by year-end.IRON
Leerink Global Healthcare Conference 20269 Mar 2026 - Multiple late-stage programs advance toward pivotal data and regulatory milestones in 2024.IRON
TD Cowen 46th Annual Health Care Conference3 Mar 2026